#### Risk of bias
| Bias | Authors' judgement | Support for judgement |
|---|---|---|
| Baseline profile: Anticholinergic use | Unclear risk | No other information available. |
| Baseline profile: β2 agonist use | Unclear risk | No other information available. |
| Baseline profile: Corticosteroid use | High risk | Pretreatment of 44% in both roflumilast and placebo groups. |

### Outcomes
| Outcome or subgroup title | Statistical method | Effect size |
|---|---|---|
| FEV₁ | Mean Difference (IV, Fixed, 95% CI) | 38.00 [15.86, 60.14] |
| FVC | Mean Difference (IV, Fixed, 95% CI) | 101.00 [59.42, 142.58] |
| PEF | Mean Difference (IV, Fixed, 95% CI) | 4.21 [0.08, 8.34] |
| Exacerbations (No of subjects) | Odds Ratio (M-H, Fixed, 95% CI) | 0.82 [0.59, 1.15] |
| Exacerbations (Exacerbation rate, Inverse variance) | Rate Ratio (IV, Fixed, 95% CI) | 0.93 [0.83, 1.05] |
| Adverse effects | | |
| Diarrhea | Odds Ratio (M-H, Fixed, 95% CI) | 2.50 [1.57, 4.00] |
| Nausea | Odds Ratio (M-H, Fixed, 95% CI) | 2.78 [1.52, 5.06] |
| Headache | Odds Ratio (M-H, Fixed, 95% CI) | 1.52 [0.82, 2.82] |
| Weight loss | Odds Ratio (M-H, Fixed, 95% CI) | 4.14 [2.61, 6.56] |
| Influenza-like symptoms | Odds Ratio (M-H, Fixed, 95% CI) | 1.49 [0.81, 2.73] |
| Upper respiratory tract infection | Odds Ratio (M-H, Fixed, 95% CI) | 0.74 [0.38, 1.43] |
| Withdrawals due to AEs | Odds Ratio (M-H, Fixed, 95% CI) | 1.61 [1.18, 2.18] |
| Mortality | Odds Ratio (M-H, Fixed, 95% CI) | 0.99 [0.50, 1.96] |

### PICO 및 근거표

Author, year: Calverley PM
Title: Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomized clinical trials
Methods: As described in separate studies above and below.
Participants
Interventions
Outcomes
Risk of bias

#### Risk of bias
| Bias | Authors' judgement | Support for judgement |
|---|---|---|
| Allocation concealment (selection bias) | Low risk | Support for judgement |
| Randomised? | Low risk | |
| Method of Randomisation described? | Low risk | |
| Blinding? | Low risk | |
| Method of Blinding described? | Low risk | |
| Description of Withdrawals and Drop outs? | Low risk | |
| Baseline profile: Anticholinergic use | Low risk | |
| Baseline profile: β2 agonist use | Low risk | |
| Baseline profile: Corticosteroid use | High risk | |

Outcome or subgroup title
Adverse effects
| Outcome or subgroup title | Statistical method | Effect size |
|---|---|---|
| No of patients experiencing AEs | Odds Ratio (M-H, Fixed, 95% CI) | 1.28 [1.11, 1.49] |
| Non-fatal serious AEs | Odds Ratio (M-H, Fixed, 95% CI) | 0.88 [0.74, 1.05] |

Author, year: Calverley PM
Title: Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomized clinical trials
Methods: Parallel group study.
Randomisation: Randomised, double blind, placebo-controlled trial
Trial duration: 52 weeks.
Intention-to-treat analysis: Stated.

<PAGE>138